TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07598825: A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-controlled Study of Inebilizumab in Participants With Autoimmune Hepatitis

Sponsor: Amgen · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 180 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$8,818,200

Rescue Site Savings

+$5,829,810

Unlock Full NCT07598825 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07598825 Rescue Dossier →